Previous Article | Next Article ![]()
Journal of Bacteriology, July 2003, p. 4186-4194, Vol. 185, No. 14
0021-9193/03/$08.00+0 DOI: 10.1128/JB.185.14.4186-4194.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Howard Hughes Medical Institute, Center for Advanced Biotechnology and Medicine, and Department of Biochemistry, Robert Wood Johnson Medical School, The University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854
Received 6 March 2003/ Accepted 16 April 2003
|
|
|---|
|
|
|---|
Biochemical analyses have indicated that response regulator proteins employ many different mechanisms for regulation of effector domain activity including inhibition, allosteric activation, dimerization or higher-order oligomerization, and interactions with heterologous partners. Numerous structures of isolated regulatory domains in their unphosphorylated and phosphorylated (or otherwise activated) states have provided details of the conformational changes associated with activation. However, a complete description of how these structural perturbations control effector domain activity has been limited by the relatively small number of structures of intact multidomain response regulator proteins available to provide information about interactions between regulatory and effector domains.
Response regulator proteins can be classified by similarities in their effector domains (39). The majority of response regulators function as transcription factors and have DNA-binding effector domains. They are subdivided into three groups termed the OmpR/PhoB, NarL/FixJ, and NtrC/DctD subfamilies. The remaining response regulator proteins contain miscellaneous effector domains, such as enzymes, and are included as a fourth subfamily. Representative multidomain structures are available for three of the four subfamilies: transcription factor DrrD (an OmpR/PhoB family member) (8), transcription factor NarL (3), and methylesterase CheB (11).
Members of the OmpR/PhoB subfamily, comprising approximately 40% of all response regulators, have been relatively resistant to crystallization. As has been the case for many recent structural projects, OmpR/PhoB homologues from thermophilic bacteria have proved more amenable to crystallization than their mesophilic counterparts (8). The genome of Thermotoga maritima encodes four response regulators of the OmpR/PhoB subfamily, designated DrrA to -D for DNA-binding response regulators (8, 30). The lack of a genetic system in T. maritima has precluded identification of the genes regulated by Drr proteins, and nothing is known of the two-component systems in which they operate. With this caveat, the Drr proteins have served as useful models for structural analysis.
The structure of DrrD provided the first structural information for an intact OmpR/PhoB family member (8). Here we report the crystal structure of DrrB. The interdomain interfaces of DrrB and DrrD are remarkably different, providing direct structural evidence for different mechanisms of regulation in two members of the same response regulator subfamily.
|
|
|---|
For purification of full-length DrrB, the soluble portion of the lysate was incubated in a 70°C water bath for 30 min to denature endogenous E. coli proteins. The denatured proteins were removed by centrifugation at 4,900 x g for 30 min. All subsequent steps were carried out at 25°C. The remaining thermostable protein was precipitated by addition of 1.5 volumes of a saturated solution of ammonium sulfate (60% saturation, final) and collected by centrifugation. The ammonium sulfate pellet was resuspended in buffer A, filtered through a 0.45-µm-pore-size filter, loaded onto a 10-ml HiTrap Blue column (Amersham Biosciences), and eluted with a 0 to 1.0 M gradient of NaCl in buffer A. DrrB eluted at
0.4 M NaCl. Fractions containing DrrB were pooled and precipitated by addition of a saturated solution of ammonium sulfate to 60% saturation. The ammonium sulfate pellet was resuspended in 12.5 mM Tris-Cl (pH 8.0)-1.0 M NaCl-2 mM ßME (buffer B). Ammonium sulfate (4 M) was added dropwise to a final concentration of 0.8 M, and the solution was stirred gently at room temperature for 30 min. The protein was filtered and applied to a HiLoad phenyl Sepharose 16/10 column Amersham Biosciences) equilibrated in 25 mM sodium phosphate (pH 7.0)-1.0 M ammonium sulfate-2 mM ßME. DrrB was eluted with 25 mM sodium phosphate (pH 7.0)-2 mM ßME. Fractions containing DrrB were pooled, concentrated, and subjected to gel filtration chromatography over a Superdex 75 26/60 column (Amersham Biosciences) in buffer B.
For purification of DrrB-N, the soluble portion of the sonicated lysate was incubated at 64°C for 30 min. The ammonium sulfate pellet was then resuspended in 20 mM Bis-tris [Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane] (pH 6.0)-5 mM ßME, filtered, and applied to a 70-ml MonoQ column (Amersham Biosciences). The protein was eluted with a 0.1 to 0.9 M NaCl gradient. Fractions containing DrrB-N were pooled, concentrated, and loaded onto a Superdex 75 26/60 column equilibrated in 20 mM Bis-tris (pH 6.0)-100 mM NaCl-5 mM ßME.
A selenomethionine-derivatized DrrB protein was prepared in cells grown as described previously (17, 35). Protein expression was induced with 1.0 mM IPTG, and cell growth was continued at 20°C for 12 h. Cells were harvested by centrifugation, and the protein was isolated and purified as described above for the native protein except that 10 mM ßME was added to all solutions.
Size exclusion chromatography. Fast performance liquid chromatography (FPLC) experiments were conducted with an AKTA FPLC system (Amersham Biosciences). Chromatography was performed at 4°C at a flow rate of 1.0 ml/min with a Superdex 75 10/30 column equilibrated in 12.5 mM Tris-Cl (pH 7.5)-100 mM NaCl-2 mM ßME. Absorbance was monitored at 280 nm. For each analysis, a 100-µl sample containing approximately 30 µM DrrB or DrrB-N in 12.5 mM Tris-Cl (pH 7.5)-200 mM NaCl-2 mM ßME was injected onto the column. Phosphorylated DrrB and DrrB-N were prepared by incubating proteins with 100 mM ammonium hydrogen phosphoramidate (synthesized as described in reference 36)-12.5 mM Tris-Cl (pH 7.5)-100 mM NaCl-20 mM MgCl2-2 mM ßME for 10 min at 60°C prior to injection onto the column.
Crystallization. DrrB was concentrated at 37°C to 46.5 mg/ml in 12.5 mM Tris-Cl (pH 8.0)-1.0 M NaCl-10 mM dithiothreitol with a BioMax-10 concentrator. Crystals of DrrB were grown at 37°C by the hanging drop method of vapor diffusion. The protein solution was mixed with equal volumes of the reservoir solution composed of 1.2 to 1.4 M sodium phosphate-potassium phosphate, pH 6.3 (NaH2PO4/K2HPO4 ratio, 65:35 [mol/mol]). Selenomethionine-derivatized protein crystals were grown under similar conditions. Once crystals had formed, trays containing crystals were moved to 25°C. Cryopreservation was achieved by transferring the crystals into reservoir solution containing 25% ethylene glycol. Crystals were then cooled in a 100°K nitrogen cryostream. The crystals belonged to space group P212121, with cell constants a = 57.89 Å, b = 59.39 Å, and c = 77.34 Å, corresponding to one molecule per asymmetric unit. Multiwavelength anomalous dispersion data were collected from a single crystal of selenomethionine-substituted DrrB at beamline X4A at the National Synchrotron Light Source at Brookhaven National Laboratory, Upton, N.Y. Data were processed and scaled with DENZO and SCALEPACK (32).
Structure determination and refinement.
Three of five selenomethionines in DrrB were identified with the SAD phasing protocol in the Crystallography & NMR System software suite (CNS) (7), with a mean figure of merit of 0.326 and phasing power of 1.4. Initial phase estimates were improved with solvent flipping density modification in CNS. The resulting high-quality electron density maps permitted automatic model building of DrrB to 2.0-Å resolution with the program ARP/WARP (33). Refinement was carried out by iterative cycles of maximum likelihood, simulated annealing, and temperature factor refinement in CNS and manual rebuilding in O (20) until convergence. The resolution of the model was gradually extended to 1.8 Å and 174 water molecules were added in positive-difference Fourier peaks greater then 3
. The final model, containing 217 residues, is missing the three C-terminal residues that have no discernible density. The density was also weak for residues 199 through 201, located in the loop region extending from the C-terminal end of helix
3. The final model has a crystallographic R factor of 0.198 and an Rfree value of 0.224. All residues are in the allowed region of the Ramachandran plot and exhibit favorable stereochemistry as defined by PROCHECK (23). Data collection and refinement statistics for DrrB are given in Table 1.
|
View this table: [in a new window] |
TABLE 1. Data collection and refinement statistics
|
|
|
|---|
In DrrB, the
/ß fold of the regulatory domain is analogous to that observed in other response regulators (Fig. 1A). Likewise, the topology of the winged-helix effector domain resembles that of the previously characterized winged-helix proteins including DrrD (8), OmpR (22, 26), and PhoB (5, 31). The two domains are connected by a short, well-ordered linker and pack together, forming an extensive buried interface.
![]() View larger version (51K): [in a new window] |
FIG. 1. (A and B) Structures of T. maritima DrrB (A) and DrrD (B). Shown are ribbon diagrams, with the site of phosphorylation on the ß3 strand delineated by a ball-and-stick representation of the conserved aspartate residue. (C) Interactions across the interdomain interface of DrrB. Green, 4-ß5- 5 face of the regulatory subunit of DrrB; gold, ß-sheet platform of the winged-helix domain. Residues at the interface that are involved in important interactions are shown in ball-and-stick representation. Small magenta spheres, water molecules; dotted lines, hydrogen bonds. The interface can be described as having a large hydrophobic core surrounded by a network of polar interactions, some of which are mediated by well-ordered water molecules.
|
The domain arrangement of DrrB is unlike that of DrrD. The individual regulatory and effector domains of DrrB and DrrD superimpose well, with root mean square deviations, rmsd, of 2.4 and 1.8 Å, respectively. However, when the two full-length proteins are aligned by superposition of their regulatory domains, the winged-helix domains occupy very different positions (Fig. 1A and B). In DrrD, only the distal end of helix
5 of the regulatory domain contacts the antiparallel ß-sheet platform of the DNA-binding domain. In DrrB, the domains are positioned such that the
4-ß5-
5 face of the regulatory domain packs squarely against the ß-sheet platform of the effector domain.
The interdomain interface of DrrB is 751 Å2, three times the size of the interdomain surface of DrrD. The nature of the interdomain interface of DrrB is typical of that commonly observed in other protein-protein interactions (19, 42) and is quite distinct from that seen in DrrD. The hydrophobic core of the DrrB interface comprises L87, F90, Y97, L122, and F138 (Fig. 1C). Surrounding this core are a series of polar interactions, some mediated by highly ordered water molecules with B factors of 20 to 25 Å2. The central component of this interface, and perhaps its most interesting feature, is the aromatic residue Y97.
The presence of Y97 at the domain interface of inactive DrrB is intriguing, as this residue corresponds to one of the highly conserved residues that exhibit dramatic reorientations in structures of activated regulatory domains (for reviews, see references 34 and 45). Specifically, in phosphorylated or otherwise-activated regulatory domains, a highly conserved Ser/Thr residue on ß4 reorients to allow formation of a hydrogen bond to the phospho-Asp. A conserved Tyr/Phe residue, located near the center of ß5, is repositioned to an inward orientation, occupying the space vacated by the reoriented Ser/Thr. In DrrB, this conserved residue is Y97. Presumably, DrrB activation involves the repositioning of Y97 to an inward position, thus altering prominent components of the DrrB interface.
It is logical to question whether DrrD could adopt the domain arrangement seen in the DrrB crystal structure. To assess this, the isolated regulatory and winged-helix domains of DrrD were superimposed onto the DrrB crystal structure. The interdomain interface in the resulting model was then evaluated with regard to steric complementarity, hydrogen bonds, and hydrophobic interactions. The newly created DrrD interface is 460 Å2, one-half the size of the DrrB interface. An analysis of protein-protein contacts across this interface provided no indication of juxtapositioning of hydrophobic residues or occurrence of hydrogen bonds or salt bridges in spite of the very polar nature of the domain surfaces. Shape complementarity is yet another issue. Not only does this model lack surface specificity, but also there are steric clashes across the interface where helix
4 from the regulatory domain contacts the loop between ß3 and ß4 of the winged-helix domain. These collisions are the direct result of the protrusion of the
4 helix in the DrrD regulatory domain. Together, the results of this analysis imply that unactivated DrrD is unable to adopt the same domain arrangement as that observed in the DrrB crystal structure.
Comparison of interdomain interfaces in response regulators.
There are now four full-length response regulators for which high-resolution structural data are available: NarL (2, 3), CheB (11), DrrD (8), and DrrB. Despite the overall structural similarities in the regulatory domains, the interfaces differ (Fig. 2). In all four proteins, a distinct subset of the conformationally variable
4-ß5-
5 face of the regulatory domain is used for interdomain contacts. Moreover, the biologically relevant residues of each protein are in a different environment with respect to this interdomain interface, providing a basis for diverse strategies of regulation by phosphorylation. For example, the interdomain interface in CheB is 800 Å2 and spans the
4-ß5-
5 face of the regulatory domain. The regulatory domain occludes the methylesterase catalytic triad, suggesting that relief of inhibition plays a role in regulation. The interdomain interface of NarL is also large, greater than 900 Å2. Contacts between the regulatory and effector domains in NarL consist of the N terminus of ß5 and the C-terminal regions of the
4 and
5 helices of the regulatory domain. In NarL, residues of the recognition helix participate in the interdomain interface, blocking this functional site in the inactivated structure. Phosphorylation disrupts interactions across this interface, promoting DNA binding (12, 47). As mentioned previously, the interdomain interfaces of DrrB and DrrD differ greatly in their sizes and natures. Whereas DrrB has a large, stable interface, interdomain contacts in DrrD are minimal. Additionally, as shown in Fig. 1, the recognition helices in both DrrB and DrrD are distal to the interdomain interfaces, implying that inhibition is not a result of direct obstruction of the functionally important region of the effector domain.
![]() View larger version (62K): [in a new window] |
FIG. 2. Regulatory domain surfaces involved in interdomain interfaces. (A) Ribbon diagram of a representative regulatory domain indicating the orientation of the regulatory domains depicted in panels B to E. Red, active-site Asp; gold, 4-ß5- 5 face of the regulatory domain that undergoes conformational changes in response to phosphorylation. (B to E) Space-filling models of the regulatory domains of DrrB (B), CheB (PDB accession code 1A2O [11]) (C), DrrD (1KGS [8]) (D), and NarL (1A04 [2]) (E). Red, residues involved in interdomain associations in each protein. In DrrB, this interface extends across the entire 4-ß5- 5 face of the regulatory domain and is 751 Å2. The CheB interdomain interface is 800 Å2 and also spans the majority of this surface. The DrrD interface is much smaller, 245 Å2, and is localized to the C-terminal region of helix 5. The NarL interdomain interface, 964 Å2, utilizes some residues in the 4-ß5- 5 region of the domain but also includes residues from the 3 helix and surrounding loops.
|
-loop, between the positioning helix,
2, and the recognition helix,
3 (6, 22, 27). The novelty of the ß-sheet platform previously led to postulation of a role specific to response regulators, specifically, mediating interactions with the regulatory domain. It is apparent from the structure of DrrB that this is the case. The entire surface of the platform interfaces with the regulatory domain.
There are structures available for several winged-helix domains from the OmpR/PhoB subfamily including DrrD (8), OmpR (22, 26), and PhoB, both alone (31) and bound to DNA (5). The cores of the winged-helix domains in all these proteins superimpose, with an rmsd for C
atoms of
2.0 Å. Furthermore, as previously noted, significant structural flexibility in the loop regions surrounding the recognition helix has been observed (Fig. 3). The PhoB/DNA crystal structure (5) indicates that these flexible loops are used for DNA binding and recognition and also for mediating protein-protein associations. The increased flexibility in these regions perhaps contributes to the optimal fit of the surfaces involved in protein-DNA or protein-protein contacts.
![]() View larger version (27K): [in a new window] |
FIG. 3. OmpR/PhoB subfamily winged-helix domains. Gray, ribbon diagram of a representative winged-helix domain that defines the OmpR/PhoB subfamily of response regulators; magenta, recognition helix that binds to the major groove of DNA. Effector domains of DrrB, DrrD (PDB accession code 1KGS [8]), OmpR (1OPC [26]), PhoB (1GXQ [26]), and PhoB bound to DNA (1GXP [5]) were superimposed based on the core region of the protein, defined as the three helices and six ß strands. In all proteins, the two loops flanking the recognition helix exhibit considerable conformational flexibility, as shown in the insets. The loop of DrrD (dotted line) is disordered.
|
70 promoters. While repression of transcription presumably can be achieved simply by sterically blocking proper positioning of RNA polymerase, activation is thought to involve positive contacts between response regulators and the
subunit and/or
subunit (C-terminal domain) of polymerase. Thus, while DNA binding is necessary for response regulator function, it may or may not be sufficient. Nonetheless, most in vitro characterization of the OmpR/PhoB subfamily has been limited to analysis of DNA binding. A variety of studies focused on different OmpR/PhoB subfamily members have addressed the role of the regulatory domain and its phosphorylation state on DNA-binding activity. No unified theme has emerged. It is clear that, for some OmpR/PhoB homologues, the isolated winged-helix domain is capable of binding to DNA as a dimer (5, 15, 21, 25). However, in all studied cases, the regulatory domain influences this interaction.
Inhibition. For some OmpR/PhoB family members such as PhoB, the isolated DNA-binding domain has been found to have higher affinity for DNA than the unphosphorylated intact protein (13), leading to the conclusion that the N-terminal regulatory domain exerts an inhibitory effect on the DNA-binding domain. However, note that no such inhibitory interaction has been documented for OmpR (21, 41), suggesting that this mechanism may not be common to all subfamily members.
The structures of the intact multidomain response regulators DrrB and DrrD provide no structural explanation for an inhibitory role for the N-terminal domain. The crystal structure of DrrD has only a small region of interdomain contact, most likely the consequence of crystal packing, and the N- and C-terminal domains are not expected to have a fixed orientation in solution. Although it has been noted that steric collisions between regulatory domains of DrrD are observed when intact DrrD is superimposed onto the DNA-binding domain of PhoB bound to DNA (5), there is no reason to believe that such collisions would actually occur in solution or represent a hindrance to DNA binding. For DrrB, which has a large domain interface, which is presumably altered by phosphorylation, the multidomain response regulator can be superimposed onto the DNA-bound C-terminal domain of PhoB without extensive steric collisions (Fig. 4). Contacts between the proteins occur in only one small region involving the ß3-
4 loop of the regulatory domain of the upstream monomer and the C-terminal end of helix
1 of the effector domain of the downstream monomer. Furthermore, the N-terminal domain does not interfere with any functional surface of the C-terminal domain such as the recognition helix, the transactivation loop, or the dimerization surfaces.
![]() View larger version (58K): [in a new window] |
FIG. 4. Model of DrrB bound to DNA. Shown is a ribbon schematic of the superposition of two full-length DrrB monomers onto the crystal structure of the C-terminal domain of PhoB bound to DNA (1GXP [5]). Monomers A and B are gold and green, respectively, and DNA is blue. There is only one small region of steric conflict between the ß3- 4 loop of the regulatory domain of monomer A (residues 80 to 83) and the C-terminal end of helix 1 of the DNA-binding domain of monomer B (residues 160 to 163). Thus the model provides no structural basis for a mechanism of inhibition of DNA binding by the unphosphorylated regulatory domain. This model is not expected to approximate the structure of phosphorylated DrrB bound to DNA. Surfaces of the regulatory domain are presumably altered by phosphorylation, and these alterations would be expected to affect the domain interface, as well as promote specific interactions among regulatory domains within the dimer.
|
Oligomerization of DrrB was examined by using size exclusion chromatography (Fig. 5). Unphosphorylated DrrB, a 25.5-kDa protein, migrated with an apparent molecular mass of 22.2 kDa, consistent with the monomeric state observed in the crystal structure. Phosphorylated DrrB, generated by using phosphoramidate as the phosphodonor, migrated more rapidly, with an apparent molecular mass of 42.1 kDa, indicative of a dimer. An analogous monomer-to-dimer transition with the isolated regulatory domain of DrrB was observed. Gel filtration analysis of DrrB-N, consisting of residues 1 to 117 with a calculated molecular mass of 13.6 kDa, showed apparent molecular masses of 13.8 and 27.9 kDa in its unphosphorylated and phosphorylated states, respectively. Thus the regulatory domain of DrrB appears to be sufficient to mediate phosphorylation-induced dimerization.
![]() View larger version (22K): [in a new window] |
FIG. 5. Phosphorylation of DrrB and DrrB-N induces dimerization. Size exclusion chromatography of DrrB proteins in the presence and absence of phosphoramidate was carried out with a Superdex 75 column as described in Materials and Methods. The column was calibrated (A) with albumin (66 kDa), ovalbumin (44 kDa), trypsin inhibitor (21 kDa), and RNase A (13.7 kDa) as molecular mass standards. (A) Profile of full-length DrrB and phosphorylated DrrB, which eluted at positions corresponding to molecular masses of 22.2 and 42.1 kDa, respectively. (B) Profile of DrrB-N and phosphorylated DrrB-N, which migrated with apparent molecular masses of 13.8 and 27.9 kDa, respectively.
|
Interestingly, the different domain arrangements observed in DrrB and DrrD are potentially compatible with different symmetries of N-terminal domain dimerization (Fig. 6). If the extensive interface in DrrB is maintained, at least to some extent, in the phosphorylated dimer, then the N-terminal domains would be expected to associate in a head-to-tail fashion, as dictated by the tandemly arranged C-terminal domains. The domain arrangements in DrrD are possibly more varied. If the N- and C-terminal domains of the phosphorylated protein are free to rotate about a flexible linker, as they presumably are in the unphosphorylated protein, then no restrictions on the symmetry of regulatory domains are imposed by the tandem orientation of the DNA-binding domains. The regulatory domains could dimerize with either twofold rotational or translational symmetry. While the existence of different symmetries of individual domains within a dimer is an unusual occurrence, it is not without precedent, having been previously observed in the E. coli transcription factor AraC (9, 37). The symmetry of regulatory domain dimerization in DrrB and DrrD remains to be determined, but the potential exists for significant diversity in domain arrangements among these subfamily members.
![]() View larger version (19K): [in a new window] |
FIG. 6. Possible symmetries of dimerization of OmpR/PhoB subfamily transcription factors when bound to direct repeat DNA recognition sequences. Response regulators, such as DrrB, that contain an extensive domain interface, most likely dimerize with an asymmetric orientation of their regulatory domains. Twofold rotational symmetry of the regulatory domains is unlikely, as it requires nonequivalent monomers within the dimer (gray). Response regulators such as DrrD, in which the regulatory and DNA-binding domains lack a fixed orientation, can potentially dimerize with either rotationally symmetric or asymmetric orientations of their regulatory domains. If the nature of the interface changes upon phosphorylation, then additional combinations of dimerization mechanisms are possible (dashed arrows).
|
Regardless of the presence or absence of an inhibitory function, the existence of the unphosphorylated protein as a monomer or dimer, or the ability of the unphosphorylated protein to bind to DNA, phosphorylation of the regulatory domain has been found to enhance DNA binding in all OmpR/PhoB family members that have been studied. However, a detailed understanding of the mechanisms through which this regulation is achieved is lacking. Accumulated biochemical and molecular genetics data suggest that different subfamily members may employ different mechanisms of activation. The structures of DrrB and DrrD provide structural evidence for this hypothesis. The presence of an extensive domain interface in DrrB is suggestive of mechanisms involving intramolecular communication between regulatory and DNA-binding domains, while the absence of such an interface in DrrD points to an intermolecular regulatory mechanism. Thus, fundamentally different strategies appear to be used for regulation within the OmpR/PhoB subfamily. Indeed, for response regulators, as for their eukaryotic counterparts, the small GTPases of the ras superfamily, there may be a limit to the extent that similar sequences and structures of modular domains can be used to predict specific modes of function.
This work was supported by a grant from the National Institutes of Health (GM47958). A.M.S. is an associate investigator of the Howard Hughes Medical Institute.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»